Opus Genetics Management
Management criteria checks 1/4
Opus Genetics' CEO is George Magrath, appointed in Nov 2023, has a tenure of 1.17 years. total yearly compensation is $3.15M, comprised of 3% salary and 97% bonuses, including company stock and options. directly owns 0.95% of the company’s shares, worth $433.77K. The average tenure of the management team and the board of directors is 1.2 years and 4.2 years respectively.
Key information
George Magrath
Chief executive officer
US$3.1m
Total compensation
| CEO salary percentage | 3.0% |
| CEO tenure | 1.2yrs |
| CEO ownership | 0.9% |
| Management average tenure | 1.2yrs |
| Board average tenure | 4.2yrs |
Recent management updates
Recent updates
Analyst Forecasts For Ocuphire Pharma, Inc. (NASDAQ:OCUP) Are Surging Higher
Aug 19
Investors Still Aren't Entirely Convinced By Ocuphire Pharma, Inc.'s (NASDAQ:OCUP) Revenues Despite 30% Price Jump
Jul 24Companies Like Ocuphire Pharma (NASDAQ:OCUP) Are In A Position To Invest In Growth
Jul 12Slammed 26% Ocuphire Pharma, Inc. (NASDAQ:OCUP) Screens Well Here But There Might Be A Catch
May 02Ocuphire Pharma, Inc. (NASDAQ:OCUP) Shares May Have Slumped 26% But Getting In Cheap Is Still Unlikely
Mar 15Analysts Just Shaved Their Ocuphire Pharma, Inc. (NASDAQ:OCUP) Forecasts Dramatically
May 20Ocuphire Pharma, Inc. Just Beat Revenue Estimates By 42%
Apr 02We're Keeping An Eye On Ocuphire Pharma's (NASDAQ:OCUP) Cash Burn Rate
Jan 27We Think Ocuphire Pharma (NASDAQ:OCUP) Needs To Drive Business Growth Carefully
Oct 08Ocuphire completes patient enrollment for phase 2 trial of diabetic retinopathy treatment
Sep 08Ocuphire Pharma GAAP EPS of -$0.25 beats by $0.08
Aug 12Ocuphire extends IP rights for lead candidate with new U.S. patent
Aug 03Ocuphire gets new U.S. patent for its oral drug candidate APX3330 for use in diabetics
Jun 29We're Keeping An Eye On Ocuphire Pharma's (NASDAQ:OCUP) Cash Burn Rate
Jun 24Is Ocuphire Pharma (NASDAQ:OCUP) In A Good Position To Invest In Growth?
Mar 22Here's Why We're Not Too Worried About Ocuphire Pharma's (NASDAQ:OCUP) Cash Burn Situation
Oct 08Ocuphire Pharma: An Undervalued Ophthalmic Play
Aug 05CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | -US$27m |
| Jun 30 2024 | n/a | n/a | -US$14m |
| Mar 31 2024 | n/a | n/a | -US$11m |
| Dec 31 2023 | US$3m | US$96k | -US$10m |
Compensation vs Market: George's total compensation ($USD3.15M) is above average for companies of similar size in the US market ($USD645.47K).
Compensation vs Earnings: Insufficient data to compare George's compensation with company performance.
CEO
George Magrath (40 yo)
1.2yrs
Tenure
US$3,146,518
Compensation
Mr. George Magrath, MD, MBA, Ms. serves as CEO & Director of Opus Genetics, Inc. (formerly known as Ocuphire Pharma, Inc.) since November 1, 2023. He was an Analyst at Edison Investment Research Limited si...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Director | 1.2yrs | US$3.15m | 0.95% $ 433.8k | |
| Senior Vice President of Corporate Development & Secretary | no data | US$789.92k | 0.34% $ 156.2k | |
| Chief Medical Advisor | no data | US$662.10k | 0.23% $ 104.9k | |
| Senior Vice President of Finance | no data | US$789.92k | 0.024% $ 11.2k | |
| Chief Financial Officer | less than a year | no data | 0.48% $ 217.5k | |
| Chief Operating Officer | 1.2yrs | no data | 0.0063% $ 2.9k | |
| Chief Scientific & Development Officer | less than a year | no data | 0.25% $ 113.8k | |
| Head of Market Development & Commercialization | 3yrs | no data | no data | |
| Director & Corporate Controller | no data | no data | no data |
1.2yrs
Average Tenure
46yo
Average Age
Experienced Management: IRD's management team is not considered experienced ( 1.2 years average tenure), which suggests a new team.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Director | 1.2yrs | US$3.15m | 0.95% $ 433.8k | |
| Independent Director | 4.2yrs | US$154.81k | 0.45% $ 204.6k | |
| Member of Medical Advisory Board | no data | no data | no data | |
| Independent Director | 4.2yrs | US$1.35m | 0.52% $ 236.4k | |
| Member of Medical Advisory Board | 2.3yrs | no data | no data | |
| Member of Medical Advisory Board | no data | no data | no data | |
| Member of Medical Advisory Board | 5yrs | no data | no data | |
| Independent Director | 4.2yrs | US$135.34k | 0.31% $ 143.4k | |
| Independent Chairman | 4.2yrs | US$174.62k | 0.11% $ 52.1k | |
| Lead Independent Director | 4.2yrs | US$149.56k | 0.15% $ 68.5k | |
| Member of Medical Advisory Board | 3.1yrs | no data | no data | |
| Member of Medical Advisory Board | 3.1yrs | no data | no data |
4.2yrs
Average Tenure
58yo
Average Age
Experienced Board: IRD's board of directors are considered experienced (4.2 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/10 07:23 |
| End of Day Share Price | 2025/01/10 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Opus Genetics, Inc. is covered by 5 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| James Molloy | Alliance Global Partners |
| John Newman | Canaccord Genuity |
| Kristen Kluska | Cantor Fitzgerald & Co. |